MX2019001324A - Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel. - Google Patents

Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel.

Info

Publication number
MX2019001324A
MX2019001324A MX2019001324A MX2019001324A MX2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A
Authority
MX
Mexico
Prior art keywords
ocs
skin
treat inflammatory
oxygenated cholesterol
lesions
Prior art date
Application number
MX2019001324A
Other languages
English (en)
Inventor
Ren Shunlin
E Brown James
Tamraz Wilma
Lin Weiqi
Jean Kim Mee
R Miksztal Andrew
Wu Hongwei
L Lee Min
Theeuwes Felix
Ching Su Huey-
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of MX2019001324A publication Critical patent/MX2019001324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para el tratamiento y el tratamiento profiláctico de las enfermedades inflamatorias de la piel y las lesiones de la piel. Por ejemplo, los métodos pueden involucrar poner la piel en contacto con un sulfato de colesterol oxigenado (OCS), por ejemplo, con el 3-sulfato de 5-colesteno-3, 25-diol (25HC3S), con o una sal farmacéuticamente aceptable del mismo.
MX2019001324A 2016-08-02 2017-08-01 Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel. MX2019001324A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370036P 2016-08-02 2016-08-02
US201762470576P 2017-03-13 2017-03-13
PCT/US2017/044821 WO2018026767A1 (en) 2016-08-02 2017-08-01 Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions

Publications (1)

Publication Number Publication Date
MX2019001324A true MX2019001324A (es) 2019-07-04

Family

ID=61073120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001324A MX2019001324A (es) 2016-08-02 2017-08-01 Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel.

Country Status (12)

Country Link
US (2) US20190374554A1 (es)
EP (1) EP3493671A4 (es)
JP (2) JP2019524774A (es)
KR (2) KR20230124756A (es)
CN (1) CN109862787A (es)
AU (2) AU2017306140A1 (es)
BR (1) BR112019001193A2 (es)
CA (1) CA3031211A1 (es)
IL (1) IL264389A (es)
MX (1) MX2019001324A (es)
TW (2) TW201818944A (es)
WO (1) WO2018026767A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
SI3494125T1 (sl) 2016-08-02 2022-10-28 Virginia Commonwealth University Sestavki, ki vsebujejo 5-holesten-3, 25-diol, 3-sulfat(25HC3S) ali njegovo farmacevtsko sprejemljivo sol in vsaj en cikličen oligosaharid
AU2021221109A1 (en) * 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
CN113040140B (zh) * 2021-01-28 2022-06-03 菲吉乐科(南京)生物科技有限公司 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用
CN113521094A (zh) * 2021-05-23 2021-10-22 广州奇维生物信息技术有限公司 一种治疗湿疹的乳剂软膏及其制备方法
CN114646702B (zh) * 2022-03-03 2023-01-06 四川大学华西医院 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US20120253143A1 (en) * 2011-04-04 2012-10-04 Raphael Warren Method of measuring a skin agent transferred to skin
EP3239163A1 (en) 2012-04-12 2017-11-01 Virginia Commonwealth University A novel cholesterol metabolite, 5-cholesten-3,25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
US10272097B2 (en) * 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)

Also Published As

Publication number Publication date
EP3493671A4 (en) 2020-04-08
IL264389A (en) 2019-02-28
TW202308651A (zh) 2023-03-01
KR102568036B1 (ko) 2023-08-17
AU2022205208A1 (en) 2022-08-04
WO2018026767A1 (en) 2018-02-08
CN109862787A (zh) 2019-06-07
EP3493671A1 (en) 2019-06-12
TW201818944A (zh) 2018-06-01
AU2017306140A1 (en) 2019-02-21
JP2022031733A (ja) 2022-02-22
BR112019001193A2 (pt) 2019-04-30
US20210169902A1 (en) 2021-06-10
US20190374554A1 (en) 2019-12-12
JP2019524774A (ja) 2019-09-05
KR20190032530A (ko) 2019-03-27
CA3031211A1 (en) 2018-02-08
KR20230124756A (ko) 2023-08-25

Similar Documents

Publication Publication Date Title
MX2019001324A (es) Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel.
HK1245010A1 (zh) 用於治療疾病的遺傳修飾的細胞、組織和器官
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
MX2021011641A (es) Usos de sulfatos de colesterol oxigenados (soc).
EP4183806A3 (en) Glycan-interacting compounds and methods of use
PH12017500032A1 (en) Improved a� protofibril binding antibodies
WO2014151456A3 (en) Treatment of inflammatory diseases
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
WO2014144932A3 (en) Methods of using zscan4 for rejuvenating human cells
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
MX356814B (es) Métodos y composiciones para neuroprotección.
EP3471748A4 (en) AGENTS AND METHODS FOR DIAGNOSING AND TREATING DISEASES ASSOCIATED WITH EXTRACELLULAR MATRIX RENEWAL
EA201792282A1 (ru) Способы лечения заболеваний
EA201990436A1 (ru) Применение окисленных сульфатов холестерина (осх) для лечения воспалительных заболеваний кожи и кожных повреждений
EP3189847A4 (en) Therapeutic or prophylactic agent for itching skin diseases
EP3165226A4 (en) Method for treating patients having cancerous skin diseases (variants)
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
EP3755693A4 (en) AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES
AU2016902338A0 (en) Agents and methods for the diagnosis and treatment of disease